Citius Pharmaceuticals regains Nasdaq compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 8, 2025 8:34 AM EDTCRANFORD, N.J. Â , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that for 10 consecutive trading days, from June 20, 2025 to July 3, 2025, the closing bid price of the Company's common stock was at... More
